Chronic myeloid leukemia in nagpur is a type of blood cancer originating in the myeloid cells or stem cells within the bone marrow. Also known as chronic myelogenous leukemia or chronic granulocytic leukemia, this condition has evolved from being a life-threatening illness to a manageable chronic condition with the aid of therapy. Many individuals with CML can now expect normal lifespans, thanks to advancements in treatment.
CML is relatively prevalent, affecting approximately 1 in 565 individuals in the United States. It constitutes around 15% of all leukemia cases. While CML can occur at any age, it primarily impacts older adults.
Healthcare providers may suspect chronic myeloid leukemia (CML) based on abnormal blood test results. However, the diagnosis of CML is confirmed through chromosome or genetic tests that identify specific genetic changes or mutations. Common diagnostic tests for CML include:
Complete blood count (CBC): Providers may observe elevated levels of white blood cells or reduced levels of red blood cells.
Bone marrow aspiration or biopsy: Small samples of bone marrow fluid or tissue are collected for genetic testing. A medical pathologist analyzes these samples to examine the genetic makeup of abnormal cells.
Computed tomography (CT) scan: This imaging test helps assess if CML has affected other areas of the body.
Ultrasound: Providers may perform this test to determine if the spleen is enlarged, which is a common symptom of CML.
Healthcare providers commonly treat chronic phase chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKIs), which are a form of targeted therapy. In CML, TKIs target the abnormal BCR-ABL enzymes responsible for the uncontrolled division and proliferation of abnormal white blood cells. By blocking these enzymes, TKIs induce cell death in CML cells.
The advent of TKIs has significantly improved outcomes for individuals with chronic myeloid leukemia. Prior to TKIs, only approximately 20% of patients survived five years post-diagnosis. However, TKIs have drastically altered this prognosis for individuals with early-stage (chronic phase) CML.
TKIs are effective in achieving remission in chronic myeloid leukemia, defined as the absence of CML symptoms and the absence of disease signs in tests. Most patients typically continue TKI therapy for the duration of their lives. Nonetheless, recent research indicates that CML can remain in remission even after discontinuation of TKIs, leading to a state known as treatment-free remission.
WhatsApp us